Jahrestagung der Österreichischen Gesellschaft für Rheumatologie & Rehabilitation 28. - 30. November 2013 Abstracts der Posterpräsentationen Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen 2013; 20 (4): 141-165 Volltext (PDF) Übersicht
| ||||||||||||||||||
Abbildung 5: ÖGR-Jahrestagung 2013 Studenic P, et al. Proportion of patients treated with conventional synthetic (cs) DMARDSs, combination treatment of csDMARDs with either tumour-necrosis factor inhibitors (TNFi) or non-TNFi-biological originator (bo) DMARDS, and monotherapy with boDMARDs, for each sequential treatment course in percent. |
![]()
Abbildung 5: ÖGR-Jahrestagung 2013
Studenic P, et al. Proportion of patients treated with conventional synthetic (cs) DMARDSs, combination treatment of csDMARDs with either tumour-necrosis factor inhibitors (TNFi) or non-TNFi-biological originator (bo) DMARDS, and monotherapy with boDMARDs, for each sequential treatment course in percent. |